Melanoma risk during immunomodulating treatment
Immunosuppressive therapy is standard for the treatment of inflammatory diseases and for minimizing rejection in transplant patients. However, immunosuppressant drugs are associated with an increased risk of certain cancers. In particular, melanoma is an immunogenic tumor and as such, is strongly influenced by the immune system. We performed this literature review to summarize the effects of commonly used immunomodulating agents on melanoma development, recurrence and progression. We outline the mechanism of action of each drug and discuss the available evidence on its influence on melanoma. Based on existing literature, w...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Review Articles Source Type: research
High-Efficacy Therapies for Treatment-Na ïve Individuals with Relapsing–Remitting Multiple Sclerosis
AbstractThere are> 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently approved by the US Food and Drug Administration for the treatment of relapsing–remitting multiple sclerosis (RRMS). Given the multitude of available treatment options, and recent international consensu s guidelines offering differing recommendations, there is broad heterogeneity in how the DMTs are used in clinical practice. Choosing a DMT for newly diagnosed patients with MS is currently a topic of significant debate in MS care. Historically, an escalation approach to DMT was used for newly diagn osed p...
Source: CNS Drugs - November 9, 2022 Category: Neurology Source Type: research
Recurrent skin infections associated with natalizumab treatment
(Source: Neurological Sciences)
Source: Neurological Sciences - November 4, 2022 Category: Neurology Source Type: research
Medications and the risk of perforated appendicitis: an adverse event report system (FAERS) database analysis
CONCLUSION: Findings from the FAERS database highlight the risk of appendiceal perforation in the context of different classes of drugs. Larger pharmacovigilance studies are needed to confirm these observations as well as overcome inherent reporting biases.PMID:36322707 | DOI:10.1080/17474124.2022.2143346 (Source: Expert Review of Gastroenterology and Hepatology)
Source: Expert Review of Gastroenterology and Hepatology - November 2, 2022 Category: Gastroenterology Authors: Daryl Ramai Daniel Mozell Antonio Facciorusso Anjali Kewalramani Saurabh Chandan Banreet Dhindsa Amaninder Dhaliwal Shahab Khan Douglas G Adler Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
G öttingen pigs as a potential model for natalizumab pharmacokinetics, pharmacodynamics, and immunogenicity evaluation
Biomed Pharmacother. 2022 Oct 26;156:113926. doi: 10.1016/j.biopha.2022.113926. Online ahead of print.ABSTRACTNatalizumab is a recombinant, humanized form of a monoclonal antibody that binds to CD49d. The presented study was conducted to explore the suitability of Göttingen pigs as a pharmacokinetic/pharmacodynamic model in the preclinical phase of biosimilar natalizumab development. The minipigs were treated with 1.286 or 3.0 mg of natalizumab (Tysabri®) per kg of body weight by a single 1-hour intravenous infusion. Six days before (baseline) and 30 days after administration of the single dose of natalizumab, blood samp...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 29, 2022 Category: Drugs & Pharmacology Authors: Tomasz Grabowski Rafa ł Derlacz Artur Burma ńczuk Source Type: research
